» Articles » PMID: 30378706

Can Type 2 Diabetes Be Reversed and How Can This Best Be Achieved? James Lind Alliance Research Priority Number One

Overview
Journal Diabet Med
Specialty Endocrinology
Date 2018 Nov 1
PMID 30378706
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The James Lind Alliance, in association with Diabetes UK, conducted a survey of people with Type 2 diabetes to establish their priorities for research. The number one research priority was found to be 'Can Type 2 diabetes be cured or reversed, what is the best way to achieve this, and is there a point beyond which the condition cannot be reversed?'. The present review summarizes the current understanding of weight loss-induced reversal of Type 2 diabetes. It considers the diagnostic criteria for remission and describes the clinical features of post-diabetes. It is of great importance to recognize these, as post-diabetes differs considerably from the high cardiovascular risk state of prediabetes. Current data demonstrate long-term stable β-cell function, providing weight regain is prevented. If an individual, having previously demonstrated susceptibility to Type 2 diabetes, returns to their previous weight then recurrence of the condition is certain. Appropriate use of the terms 'reversal' and 'remission' is discussed, with emphasis that the word 'cure' is inappropriate. Evidence-based means of achieving and maintaining remission of Type 2 diabetes are described, together with a summary of the information on the steadily diminishing chance of achieving reversal with increasing duration of Type 2 diabetes.

Citing Articles

Sleep patterns and risks of incident cardiovascular disease and mortality among people with type 2 diabetes: a prospective study of the UK Biobank.

Hu J, Wang X, Cheng L, Dang K, Ming Z, Tao X Diabetol Metab Syndr. 2024; 16(1):15.

PMID: 38212811 PMC: 10782582. DOI: 10.1186/s13098-024-01261-8.


Global research trends of diabetes remission: a bibliometric study.

Yang X, He Z, Chen Q, Chen Y, Chen G, Liu C Front Endocrinol (Lausanne). 2023; 14:1272651.

PMID: 38089622 PMC: 10715259. DOI: 10.3389/fendo.2023.1272651.


Psycho-social factors associated with type two diabetes remission through lifestyle intervention: A scoping review.

Hart K, Kubilius A, Clark M PLoS One. 2023; 18(11):e0294344.

PMID: 37972024 PMC: 10653481. DOI: 10.1371/journal.pone.0294344.


Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial.

Yang X, He Z, Yuan L, Huang W, Li D, Xiang P BMC Endocr Disord. 2023; 23(1):215.

PMID: 37814256 PMC: 10563270. DOI: 10.1186/s12902-023-01461-9.


Induction of remission in diabetes by lowering blood glucose.

Weir G, Bonner-Weir S Front Endocrinol (Lausanne). 2023; 14:1213954.

PMID: 37409234 PMC: 10318898. DOI: 10.3389/fendo.2023.1213954.